Maven Securities LTD Invests $866,000 in SOPHiA GENETICS SA $SOPH

Maven Securities LTD acquired a new stake in shares of SOPHiA GENETICS SA (NASDAQ:SOPH) in the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor acquired 150,000 shares of the company’s stock, valued at approximately $866,000.

Several other hedge funds have also made changes to their positions in the stock. Silverberg Bernstein Capital Management LLC grew its position in SOPHiA GENETICS by 8.7% during the first quarter. Silverberg Bernstein Capital Management LLC now owns 51,970 shares of the company’s stock worth $257,000 after buying an additional 4,155 shares in the last quarter. Dimensional Fund Advisors LP raised its holdings in SOPHiA GENETICS by 24.7% in the 3rd quarter. Dimensional Fund Advisors LP now owns 31,332 shares of the company’s stock valued at $148,000 after acquiring an additional 6,205 shares in the last quarter. Principal Financial Group Inc. raised its holdings in SOPHiA GENETICS by 0.7% in the 1st quarter. Principal Financial Group Inc. now owns 1,409,242 shares of the company’s stock valued at $6,976,000 after acquiring an additional 9,800 shares in the last quarter. First Dallas Securities Inc. bought a new stake in shares of SOPHiA GENETICS in the 1st quarter worth approximately $50,000. Finally, Squarepoint Ops LLC bought a new stake in shares of SOPHiA GENETICS in the 3rd quarter worth approximately $49,000. Institutional investors own 31.59% of the company’s stock.

Insider Activity at SOPHiA GENETICS

In other SOPHiA GENETICS news, CEO Jurgi Camblong sold 50,069 shares of the company’s stock in a transaction on Friday, June 26th. The stock was sold at an average price of $5.80, for a total value of $290,400.20. Following the sale, the chief executive officer directly owned 3,601,493 shares in the company, valued at $20,888,659.40. This represents a 1.37% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Zhenyu Xu sold 17,000 shares of the stock in a transaction on Friday, August 7th. The stock was sold at an average price of $7.29, for a total value of $123,930.00. Following the transaction, the insider owned 590,887 shares of the company’s stock, valued at $4,307,566.23. This represents a 2.80% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 336,342 shares of company stock valued at $2,154,775 in the last 90 days. 4.88% of the stock is owned by corporate insiders.

SOPHiA GENETICS Stock Performance

NASDAQ:SOPH opened at $8.36 on Wednesday. The firm has a market capitalization of $701.36 million, a PE ratio of -7.27 and a beta of 0.98. The company has a quick ratio of 2.55, a current ratio of 2.69 and a debt-to-equity ratio of 0.58. SOPHiA GENETICS SA has a 12-month low of $3.10 and a 12-month high of $8.98. The firm has a 50-day moving average price of $6.89 and a 200 day moving average price of $5.63.

SOPHiA GENETICS (NASDAQ:SOPH) last released its quarterly earnings data on Wednesday, August 5th. The company reported ($0.26) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.21) by ($0.05). SOPHiA GENETICS had a negative net margin of 93.86% and a negative return on equity of 132.47%. The company had revenue of $23.31 million for the quarter, compared to analyst estimates of $21.72 million. Research analysts anticipate that SOPHiA GENETICS SA will post -0.77 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several brokerages have recently weighed in on SOPH. Weiss Ratings reissued a “sell (d-)” rating on shares of SOPHiA GENETICS in a report on Friday, July 17th. BTIG Research raised their target price on SOPHiA GENETICS from $8.00 to $9.00 and gave the stock a “buy” rating in a research report on Wednesday, August 5th. Zacks Research raised SOPHiA GENETICS to a “hold” rating in a research report on Tuesday, July 21st. Finally, HC Wainwright lifted their price target on shares of SOPHiA GENETICS from $12.00 to $14.00 and gave the stock a “buy” rating in a research note on Wednesday, August 5th. Three research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, SOPHiA GENETICS currently has an average rating of “Hold” and an average target price of $10.00.

About SOPHiA GENETICS

SOPHiA GENETICS SA is a data-driven medicine company founded in 2011 and headquartered in La Tène, Switzerland. The firm develops and operates a cloud-native software platform designed to standardize and analyze complex genomic and radiomic data. Its core offering, the SOPHiA DDM™ platform, leverages artificial intelligence and machine learning algorithms to help healthcare institutions, laboratories and biopharmaceutical partners derive actionable insights from next-generation sequencing and medical imaging datasets.

The SOPHiA DDM™ platform supports a range of clinical applications, including oncology, hereditary diseases and rare genetic disorders.